Trial Profile
A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Agitation
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 24 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2022 This trial has been completed in Bulgaria according to European Clinical Trials Database record.
- 27 Jun 2022 Planned End Date changed from 1 Jul 2022 to 1 Sep 2022.